Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Nurix Therapeutics's enterprise value was $683.24M on Nov 11, 2026, against $930.31M a year earlier. Over the last 5 years it ranged from $12.24M to $2.23B, with a median of $411.20M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $683.24M | -33.6% |
| 2025 | Dec 31, 2025 | $1.03B | +26.2% |
| 2024 | Dec 31, 2024 | $815.75M | +237.6% |
| 2023 | Dec 29, 2023 | $241.66M | +39.5% |
| 2022 | Dec 30, 2022 | $173.20M | -81.7% |
| 2021 | Dec 31, 2021 | $946.02M | +2.5% |
| 2020 | Dec 31, 2020 | $922.99M | – |
See a number that looks wrong?